Passage Bio Inc (PASG) is a clinical-stage genetic medicines company based in the United States. The company focuses on developing transformative therapies for rare, monogenic central nervous system (CNS) diseases. Its proprietary technology platform allows the company to develop viral vector-mediated gene therapies with the potential to restore function to cells damaged by disease. As of September 2021, Passage Bio's lead product candidate, PBGM01, was in a Phase 1/2a clinical trial for the treatment of infantile GM1 gangliosidosis, a rare and life-threatening genetic disorder. The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Passage Bio Inc (PASG) is a clinical-stage genetic medicines company based in the United States. The company focuses on developing transformative therapies for rare, monogenic central nervous system (CNS) diseases. Its proprietary technology platform allows the company to develop viral vector-mediated gene therapies with the potential to restore function to cells damaged by disease. As of September 2021, Passage Bio's lead product candidate, PBGM01, was in a Phase 1/2a clinical trial for the treatment of infantile GM1 gangliosidosis, a rare and life-threatening genetic disorder. The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.